| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CCNB1; CCNB; G2/mitotic-specific cyclin-B1 |
| Entrez GeneID | 891 |
| WB Predicted band size | Calculated MW: 48 kDa; Observed MW: 55 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human Cyclin B1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于Cyclin B1抗体的参考文献示例(注：文献为示例性质，非真实存在)：
---
1. **"Cyclin B1 Expression Predicts Poor Prognosis in Colorectal Cancer"**
*Authors: Johnson R., et al.*
**摘要**：通过免疫组化(IHC)分析结直肠癌组织中Cyclin B1的表达水平，发现其高表达与肿瘤分期进展和患者生存率降低显著相关，提示Cyclin B1可作为潜在预后标志物。
2. **"A Comparative Study of Cyclin B1 Antibodies in Flow Cytometry"**
*Authors: Chen L., Wang H.*
**摘要**：评估四种商业来源的Cyclin B1抗体在流式细胞术中的性能，确定抗体Clone X-102在同步化HeLa细胞中检测G2/M期特异性表达的灵敏度最佳。
3. **"Cyclin B1 Antibody-Based Detection of Mitotic Arrest in Drug Screening"**
*Authors: Gupta S., et al.*
**摘要**：开发基于Cyclin B1抗体(WB/IF验证)的高通量筛选方法，用于评估抗癌药物诱导的细胞有丝分裂停滞效应，并验证其与细胞毒性相关性。
4. **"Mechanistic Insights into Cyclin B1 Degradation Using siRNA and Antibody Tracking"**
*Authors: Müller P., et al.*
**摘要**：结合siRNA敲低和Cyclin B1抗体实时成像，揭示其在有丝分裂退出阶段的泛素化降解动态，为细胞周期调控机制提供新证据。
---
这些示例涵盖了Cyclin B1抗体在癌症预后、实验方法开发、药物筛选及基础机制研究中的应用。如需真实文献，建议通过PubMed或Google Scholar以关键词“Cyclin B1 antibody”、“Cyclin B1 biomarker”检索。
Cyclin B1 is a critical regulatory protein involved in cell cycle progression, specifically governing the transition from the G2 phase to mitosis (M phase). As a member of the cyclin family, it binds and activates cyclin-dependent kinase 1 (CDK1), forming the maturation-promoting factor (MPF) complex. This complex triggers key events such as nuclear envelope breakdown and chromosome condensation. Cyclin B1 expression peaks during late G2 and degrades rapidly via the ubiquitin-proteasome system during metaphase, ensuring precise cell cycle control.
Antibodies targeting Cyclin B1 are essential tools for studying its expression, localization, and function in cellular and disease contexts. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein levels across cell cycle stages or pathological conditions. In cancer research, Cyclin B1 is frequently investigated due to its dysregulation in tumors, where overexpression correlates with poor prognosis, genomic instability, and therapeutic resistance in cancers like breast, lung, and colorectal carcinomas. Such antibodies help identify Cyclin B1 as a potential biomarker or therapeutic target.
Validated Cyclin B1 antibodies demonstrate specificity through knockout/knockdown controls and recognize distinct epitopes, enabling applications in diverse samples, including cell lysates and formalin-fixed tissues. Researchers also utilize these antibodies to explore Cyclin B1's role in checkpoint adaptation, DNA damage response, and developmental biology.
×
